603590 康辰药业
已收盘 08-14 15:00:00
资讯
新帖
简况
股市必读:康辰药业新发布《北京国枫律师事务所关于北京康辰药业股份有限公司2026年第一次临时股东会的法律意见书》
证券之星 · 08-10
股市必读:康辰药业新发布《北京国枫律师事务所关于北京康辰药业股份有限公司2026年第一次临时股东会的法律意见书》
每周股票复盘:康辰药业(603590)推227.5万限制性股票激励
证券之星 · 08-09
每周股票复盘:康辰药业(603590)推227.5万限制性股票激励
康辰药业涨7.12%,山西证券二个月前给出“买入”评级
证券之星 · 08-07
康辰药业涨7.12%,山西证券二个月前给出“买入”评级
股市必读:康辰药业新发布《北京国枫律师事务所关于北京康辰药业股份有限公司2026年第一次临时股东会的法律意见书》
证券之星 · 08-07
股市必读:康辰药业新发布《北京国枫律师事务所关于北京康辰药业股份有限公司2026年第一次临时股东会的法律意见书》
康辰药业(603590)披露2026年限制性股票激励计划首次授予事项,8月6日股价上涨0.65%
证券之星 · 08-06
康辰药业(603590)披露2026年限制性股票激励计划首次授予事项,8月6日股价上涨0.65%
股市必读:康辰药业新发布《康辰药业关于股份回购进展公告》
证券之星 · 08-06
股市必读:康辰药业新发布《康辰药业关于股份回购进展公告》
康辰药业(603590)披露股份回购进展公告,8月4日股价上涨1.88%
证券之星 · 08-04
康辰药业(603590)披露股份回购进展公告,8月4日股价上涨1.88%
每周股票复盘:康辰药业(603590)召开临时股东会审议股权激励计划
证券之星 · 08-02
每周股票复盘:康辰药业(603590)召开临时股东会审议股权激励计划
康辰药业(603590)披露部分闲置募集资金现金管理赎回公告,7月31日股价上涨0.88%
证券之星 · 07-31
康辰药业(603590)披露部分闲置募集资金现金管理赎回公告,7月31日股价上涨0.88%
康辰药业:公司2025年境外地区营业收入较2024年增长30%
证券之星 · 07-31
康辰药业:公司2025年境外地区营业收入较2024年增长30%
康辰药业:公司历年归母净利润均为正数
证券之星 · 07-31
康辰药业:公司历年归母净利润均为正数
康辰药业:截至2025年12月31日的股东总数为11,755户
证券之星 · 07-31
康辰药业:截至2025年12月31日的股东总数为11,755户
股市必读:新发布《康辰药业2026年第一次临时股东会会议资料》
证券之星 · 07-31
股市必读:新发布《康辰药业2026年第一次临时股东会会议资料》
康辰药业(603590)披露2026年限制性股票激励计划草案,7月29日股价上涨0.16%
证券之星 · 07-29
康辰药业(603590)披露2026年限制性股票激励计划草案,7月29日股价上涨0.16%
每周股票复盘:康辰药业(603590)公布2026年限制性股票激励计划
证券之星 · 07-19
每周股票复盘:康辰药业(603590)公布2026年限制性股票激励计划
7月17日康辰药业跌9.02%,富达悦享红利优选混合A基金重仓该股
证券之星 · 07-17
7月17日康辰药业跌9.02%,富达悦享红利优选混合A基金重仓该股
康辰药业(603590)披露2026年限制性股票激励计划首次授予激励对象名单核查意见及公示情况说明,7月14日股价上涨4.53%
证券之星 · 07-14
康辰药业(603590)披露2026年限制性股票激励计划首次授予激励对象名单核查意见及公示情况说明,7月14日股价上涨4.53%
每周股票复盘:康辰药业(603590)拟推245.5万股市值激励
证券之星 · 07-05
每周股票复盘:康辰药业(603590)拟推245.5万股市值激励
康辰药业(603590.SH)拟推2026年限制性股票激励计划
智通财经 · 07-03
康辰药业(603590.SH)拟推2026年限制性股票激励计划
康辰药业涨5.34%,山西证券一个月前给出“买入”评级
证券之星 · 07-01
康辰药业涨5.34%,山西证券一个月前给出“买入”评级
加载更多
公司概况
公司名称:
北京康辰药业股份有限公司
所属行业:
医药制造业
上市日期:
2018-08-27
主营业务:
北京康辰药业股份有限公司的主营业务是创新药研发、生产与销售。公司的主要产品是注射用尖吻蝮蛇血凝酶、鲑降钙素注射液、鲑降钙素鼻用喷雾剂。公司凭借核心产品“注射用尖吻蝮蛇血凝酶”(商品名“苏灵”)荣获第八批国家级制造业单项冠军企业认定。报告期公司被授予“北京制造业企业百强”、“北京高精尖企业百强”、“北京专精特新企业百强”等荣誉资质,并通过高新技术企业重新认定,公司总裁牛战旗获“密云区首批高层次人才”称号,企业实力再获认可。
发行价格:
24.34
{"stockData":{"symbol":"603590","market":"SH","secType":"STK","nameCN":"康辰药业","latestPrice":32.73,"timestamp":1786690801000,"preClose":33.1,"halted":0,"volume":2475744,"delay":0,"changeRate":-0.0112,"floatShares":158000000,"shares":159000000,"eps":1.0609,"marketStatus":"已收盘","change":-0.37,"latestTime":"08-14 15:00:00","open":33.33,"high":33.54,"low":32.2,"amount":81000500,"amplitude":0.0405,"askPrice":32.73,"askSize":35,"bidPrice":32.72,"bidSize":15,"shortable":0,"etf":0,"ttmEps":1.0609,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":5,"adr":0,"adjPreClose":33.1,"symbolType":"stock","openAndCloseTimeList":[[1786671000000,1786678200000],[1786683600000,1786690800000]],"highLimit":36.41,"lowLimit":29.79,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":159010477,"isCdr":false,"pbRate":1.62,"roa":"--","peRate":30.851164,"roe":"1.46%","epsLYR":1.05,"committee":0.645522,"marketValue":5204000000,"turnoverRate":0.0156,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-08-17。","floatMarketCap":5179000000},"requestUrl":"/m/hq/s/603590","defaultTab":"news","newsList":[{"id":"2658707286","title":"股市必读:康辰药业新发布《北京国枫律师事务所关于北京康辰药业股份有限公司2026年第一次临时股东会的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658707286","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658707286?lang=zh_cn&edition=full","pubTime":"2026-08-10 01:51","pubTimestamp":1786297870,"startTime":"0","endTime":"0","summary":"北京国枫律师事务所关于北京康辰药业股份有限公司2026年限制性股票激励计划首次授予事项的法律意见书8月6日确定首次授予日,向63名激励对象授予227.50万股限制性股票,授予价格由15.75元/股调整为15.40元/股;授予程序合法,公司及激励对象均符合授予条件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000000808.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658675880","title":"每周股票复盘:康辰药业(603590)推227.5万限制性股票激励","url":"https://stock-news.laohu8.com/highlight/detail?id=2658675880","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658675880?lang=zh_cn&edition=full","pubTime":"2026-08-09 02:19","pubTimestamp":1786213150,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘,康辰药业报收于32.94元,较上周的29.76元上涨10.69%。本周关注点公司公告汇总:康辰药业向63名激励对象首次授予227.50万股限制性股票,授予价格为15.40元/股。公司公告汇总:康辰药业拟回购注销13,400股限制性股票,注册资本将减少至158,997,077元。同日,公司召开董事会及薪酬与考核委员会会议,确定2026年限制性股票激励计划首次授予日为2026年8月6日,向63名激励对象授予227.50万股限制性股票,授予价格由15.75元/股调整为15.40元/股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657615737","title":"康辰药业涨7.12%,山西证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2657615737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657615737?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:38","pubTimestamp":1786091882,"startTime":"0","endTime":"0","summary":"今日康辰药业涨7.12%,收盘报32.94元。2026年5月28日,山西证券研究员邓周宇,魏赟,张智勇发布了对康辰药业的研报《KAT6/7双靶点新药竞争力突出,KC1036临床提速》,该研报对康辰药业给出“买入”评级。研报中预计2026-2028年公司营收分别为10.07/11.15/12.95亿元,归母净利润1.87/2.11/2.51亿元,对应5月27日收盘价,PE为30.4/26.9/22.6倍,持续覆盖,给予“买入-B”评级。康辰药业个股概况:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700027911.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","002500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657659094","title":"股市必读:康辰药业新发布《北京国枫律师事务所关于北京康辰药业股份有限公司2026年第一次临时股东会的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657659094","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657659094?lang=zh_cn&edition=full","pubTime":"2026-08-07 01:48","pubTimestamp":1786038494,"startTime":"0","endTime":"0","summary":"北京国枫律师事务所关于北京康辰药业股份有限公司2026年限制性股票激励计划首次授予事项的法律意见书2026年8月6日确定首次授予日,向63名激励对象授予227.50万股限制性股票,授予价格由15.75元/股调整为15.40元/股;授予程序合法,公司及激励对象均符合授予条件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700001801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657307476","title":"康辰药业(603590)披露2026年限制性股票激励计划首次授予事项,8月6日股价上涨0.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657307476","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657307476?lang=zh_cn&edition=full","pubTime":"2026-08-06 22:32","pubTimestamp":1786026739,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘,康辰药业报收于30.75元,较前一交易日上涨0.65%,最新总市值为48.9亿元。该股当日开盘30.7元,最高30.85元,最低30.01元,成交额达8732.55万元,换手率为1.81%。近日,康辰药业发布《关于向2026年限制性股票激励计划激励对象首次授予限制性股票及调整授予价格的公告》。因公司实施2025年度权益分派,每股派息0.35元,根据激励计划规定,对授予价格进行调整。激励对象未发生不得授予的情形,首次授予条件已满足。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600040040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657521237","title":"股市必读:康辰药业新发布《康辰药业关于股份回购进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657521237","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657521237?lang=zh_cn&edition=full","pubTime":"2026-08-06 01:46","pubTimestamp":1785951976,"startTime":"0","endTime":"0","summary":"公司公告汇总:截至2026年7月31日,康辰药业已累计回购1,998,804股,占总股本1.26%,支付金额78,433,881.08元。公司公告汇总康辰药业关于股份回购进展公告北京康辰药业股份有限公司于2025年10月15日召开董事会,审议通过以集中竞价交易方式回购公司股份的方案,回购资金总额为5,000万元至10,000万元,价格不超过82元/股,回购期限为12个月,用途为员工持股计划或股权激励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001625.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656520045","title":"康辰药业(603590)披露股份回购进展公告,8月4日股价上涨1.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656520045","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656520045?lang=zh_cn&edition=full","pubTime":"2026-08-04 22:46","pubTimestamp":1785854777,"startTime":"0","endTime":"0","summary":"截至2026年8月4日收盘,康辰药业报收于30.4元,较前一交易日上涨1.88%,最新总市值为48.34亿元。该股当日开盘30.03元,最高30.95元,最低30.0元,成交额达8478.24万元,换手率为1.76%。近日,康辰药业发布《关于股份回购进展公告》。截至2026年7月31日,已累计回购1,998,804股,占公司总股本的1.26%,回购最高价为51.40元/股,最低价为28.36元/股,支付总金额为78,433,881.08元。本次回购符合相关法规及公司方案要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400041790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656160563","title":"每周股票复盘:康辰药业(603590)召开临时股东会审议股权激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2656160563","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656160563?lang=zh_cn&edition=full","pubTime":"2026-08-02 02:39","pubTimestamp":1785609550,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘,康辰药业报收于29.76元,较上周的31.57元下跌5.73%。本周,康辰药业7月27日盘中最高价报32.75元。本周关注点公司公告汇总:康辰药业召开2026年第一次临时股东会,审议股权激励计划草案及相关议案。康辰药业于2025年10月29日经董事会及监事会审议通过,使用不超过2.6亿元闲置募集资金进行现金管理,有效期12个月。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000747.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655362411","title":"康辰药业(603590)披露部分闲置募集资金现金管理赎回公告,7月31日股价上涨0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655362411","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655362411?lang=zh_cn&edition=full","pubTime":"2026-07-31 22:22","pubTimestamp":1785507768,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘,康辰药业报收于29.76元,较前一交易日上涨0.88%,最新总市值为47.32亿元。近日,康辰药业发布《关于使用部分闲置募集资金进行现金管理赎回的公告》。公告显示,公司于2025年10月29日召开董事会及监事会,审议通过使用不超过2.6亿元闲置募集资金进行现金管理的议案,有效期12个月。截至2026年8月1日,公司已赎回部分闲置募集资金购买的现金管理产品,本金4,000万元及收益115.20万元已归还至募集资金账户。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100042036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655355990","title":"康辰药业:公司2025年境外地区营业收入较2024年增长30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655355990","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655355990?lang=zh_cn&edition=full","pubTime":"2026-07-31 15:54","pubTimestamp":1785484464,"startTime":"0","endTime":"0","summary":"证券之星消息,康辰药业07月31日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,公司报告显示,2022 至 2024 年康辰药业海外销售收入出现大幅下滑,据碧湾APP分析,2022 年海外销售额 1052.21 万元,后续同比下滑 25.65%;国内市场同样承压,2022 年国内销售额 8.41 亿元,至 2025 年同比下降 11.81%。根据公司披露的2025年度报告显示,公司2025年境外地区营业收入较2024年增长30%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100023559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655355991","title":"康辰药业:公司历年归母净利润均为正数","url":"https://stock-news.laohu8.com/highlight/detail?id=2655355991","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655355991?lang=zh_cn&edition=full","pubTime":"2026-07-31 15:54","pubTimestamp":1785484461,"startTime":"0","endTime":"0","summary":"证券之星消息,康辰药业(603590)07月31日在投资者关系平台上答复投资者关心的问题。投资者提问:什么原因促使股价跌跌不休?一直看好本公司,不会被ST吧?康辰药业回复:尊敬的投资者,您好!股价波动受宏观经济、行业发展周期、外部环境、投资风险偏好及轮动等多种因素影响。公司历年归母净利润均为正数,持续保持盈利,资产负债率维持低位,现金流稳定;公司的营销转型与创新正在形成新的突破点,公司无触发《上海证券交易所股票上市规则》规定的退市风险警示的条件。感谢您的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100023550.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655935592","title":"康辰药业:截至2025年12月31日的股东总数为11,755户","url":"https://stock-news.laohu8.com/highlight/detail?id=2655935592","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655935592?lang=zh_cn&edition=full","pubTime":"2026-07-31 15:54","pubTimestamp":1785484446,"startTime":"0","endTime":"0","summary":"证券之星消息,康辰药业(603590)07月31日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司2025年12月底及2026年1月底的股东数量?康辰药业回复:尊敬的投资者,您好!公司会在定期报告中披露报告期末的股东总数,截至2025年12月31日的股东总数为11,755户,如需查询其他时间节点的股东总数,您可以把带有时间和姓名的股票交易软件持仓截图和身份证一并扫描发送到以下邮箱:ir@konruns.cn。公司对相关资料核实后给您回复。感谢您的关注!本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100023506.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655807979","title":"股市必读:新发布《康辰药业2026年第一次临时股东会会议资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2655807979","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655807979?lang=zh_cn&edition=full","pubTime":"2026-07-31 01:47","pubTimestamp":1785433630,"startTime":"0","endTime":"0","summary":"截至2026年7月30日收盘,康辰药业报收于29.5元,下跌5.54%,换手率1.99%,成交量3.14万手,成交额9468.05万元。公司公告汇总:康辰药业将于2026年8月6日召开2026年第一次临时股东会,审议2026年限制性股票激励计划相关议案及回购注销部分限制性股票等事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073100001373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655918338","title":"康辰药业(603590)披露2026年限制性股票激励计划草案,7月29日股价上涨0.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655918338","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655918338?lang=zh_cn&edition=full","pubTime":"2026-07-29 22:42","pubTimestamp":1785336138,"startTime":"0","endTime":"0","summary":"截至2026年7月29日收盘,康辰药业报收于31.23元,较前一交易日上涨0.16%,最新总市值为49.66亿元。该股当日开盘31.25元,最高31.69元,最低30.84元,成交额达7057.94万元,换手率为1.43%。近日,康辰药业披露《公司2026年限制性股票激励计划(草案)》及其摘要、《公司2026年限制性股票激励计划实施考核管理办法》等文件,相关议案拟提交公司2026年第一次临时股东会审议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072900040776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652237474","title":"每周股票复盘:康辰药业(603590)公布2026年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2652237474","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652237474?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:42","pubTimestamp":1784396533,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘,康辰药业报收于34.21元,较上周的31.93元上涨7.14%。本周,康辰药业7月15日盘中最高价报37.93元。本周关注点公司公告汇总:康辰药业公布2026年限制性股票激励计划首次授予名单及公示情况。公司公告汇总康辰药业董事会薪酬与考核委员会就2026年限制性股票激励计划首次授予激励对象名单出具核查意见,并完成内部公示。公司于2026年7月3日召开第五届董事会第四次会议,审议通过《2026年限制性股票激励计划(草案)》及其摘要。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652405366","title":"7月17日康辰药业跌9.02%,富达悦享红利优选混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652405366","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652405366?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:14","pubTimestamp":1784276093,"startTime":"0","endTime":"0","summary":"证券之星消息,7月17日康辰药业跌9.02%,收盘报34.21元,换手率4.42%,成交量6.99万手,成交额2.48亿元。根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共4家,其中持有数量最多的公募基金为富达基金(中国)的富达悦享红利优选混合A。富达悦享红利优选混合A的前十大重仓股如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700029547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651810431","title":"康辰药业(603590)披露2026年限制性股票激励计划首次授予激励对象名单核查意见及公示情况说明,7月14日股价上涨4.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651810431","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651810431?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:16","pubTimestamp":1784038577,"startTime":"0","endTime":"0","summary":"近日,康辰药业发布《董事会薪酬与考核委员会关于2026年限制性股票激励计划首次授予激励对象名单的核查意见及公示情况说明》公告。公告显示,公司于2026年7月3日召开第五届董事会第四次会议,审议通过《2026年限制性股票激励计划(草案)》及其摘要。公司对拟首次授予激励对象的姓名和职务在内部进行了公示,公示时间为2026年7月4日至7月13日,公示期间未收到任何异议。激励对象基本情况属实,主体资格合法有效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400049447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603590"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649947106","title":"每周股票复盘:康辰药业(603590)拟推245.5万股市值激励","url":"https://stock-news.laohu8.com/highlight/detail?id=2649947106","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649947106?lang=zh_cn&edition=full","pubTime":"2026-07-05 02:50","pubTimestamp":1783191020,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,康辰药业报收于31.71元,较上周的28.13元上涨12.73%。本周关注点公司公告汇总:康辰药业拟推245.5万股市值限制性股票激励计划,首次授予63人。授予总数245.5万股,占公司股本1.54%,所有激励对象获授股份未超过公司总股本的1%。北京康辰药业股份有限公司2026年限制性股票激励计划(草案)摘要公告:拟授予限制性股票245.50万股,占公司总股本的1.54%,首次授予227.50万股,预留18.00万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648766625","title":"康辰药业(603590.SH)拟推2026年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2648766625","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648766625?lang=zh_cn&edition=full","pubTime":"2026-07-03 20:56","pubTimestamp":1783083400,"startTime":"0","endTime":"0","summary":"智通财经APP讯,康辰药业(603590.SH)披露2026年限制性股票激励计划(草案),拟向激励对象授予的限制性股票数量为245.5万股,占激励计划草案公告时公司股本总额的1.54%。其中首次授予227.5万股,预留授予18万股。拟首次授予的激励对象总人数为63人。授予限制性股票的授予价格(含预留)为15.75元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603590","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648515749","title":"康辰药业涨5.34%,山西证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2648515749","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648515749?lang=zh_cn&edition=full","pubTime":"2026-07-01 16:36","pubTimestamp":1782894965,"startTime":"0","endTime":"0","summary":"今日康辰药业涨5.34%,收盘报30.56元。2026年5月28日,山西证券研究员邓周宇,魏赟,张智勇发布了对康辰药业的研报《KAT6/7双靶点新药竞争力突出,KC1036临床提速》,该研报对康辰药业给出“买入”评级。研报中预计2026-2028年公司营收分别为10.07/11.15/12.95亿元,归母净利润1.87/2.11/2.51亿元,对应5月27日收盘价,PE为30.4/26.9/22.6倍,持续覆盖,给予“买入-B”评级。此外,太平洋研究员谭紫媚,张懿,中航证券研究员李蔚近期也对该股发布了研报,同样给出“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100031152.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603590","002500"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786740812887,"stockEarnings":[{"period":"1week","weight":-0.0064},{"period":"1month","weight":-0.112},{"period":"3month","weight":-0.0571},{"period":"6month","weight":-0.215},{"period":"1year","weight":-0.4257},{"period":"ytd","weight":-0.1676}],"compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0072},{"period":"3month","weight":-0.0503},{"period":"6month","weight":-0.0379},{"period":"1year","weight":0.0711},{"period":"ytd","weight":-0.0105}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京康辰药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15241人(较上一季度增加29.66%)","perCapita":"10381股","listingDate":"2018-08-27","address":"北京市密云区经济开发区兴盛南路11号","registeredCapital":"15901万元","survey":" 北京康辰药业股份有限公司的主营业务是创新药研发、生产与销售。公司的主要产品是注射用尖吻蝮蛇血凝酶、鲑降钙素注射液、鲑降钙素鼻用喷雾剂。公司凭借核心产品“注射用尖吻蝮蛇血凝酶”(商品名“苏灵”)荣获第八批国家级制造业单项冠军企业认定。报告期公司被授予“北京制造业企业百强”、“北京高精尖企业百强”、“北京专精特新企业百强”等荣誉资质,并通过高新技术企业重新认定,公司总裁牛战旗获“密云区首批高层次人才”称号,企业实力再获认可。","listedPrice":24.34},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康辰药业(603590)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康辰药业,603590,康辰药业股票,康辰药业股票老虎,康辰药业股票老虎国际,康辰药业行情,康辰药业股票行情,康辰药业股价,康辰药业股市,康辰药业股票价格,康辰药业股票交易,康辰药业股票购买,康辰药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康辰药业(603590)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康辰药业(603590)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}